Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.

The present invention relates to Quinazolinyl derivatives polymorph, process and composition thereof. (I) ##STR00001##

The present invention relates to Quinazolinyl derivatives polymorph, process and composition thereof. (I) ##STR00001##

Disclosed are a crystal of a maleate of a compound of formula (I), a preparation method for the crystal, a crystallization composition of same, a pharmaceutical composition of same, and uses thereof in preventing and treating a tumor.

##STR00001##

In one aspect, the present disclosure provides caffeic acid derivatives of the formula:

##STR00001##

wherein the variables are as defined herein. In another aspect, the present disclosure provides pharmaceutical compositions and methods of using of the compounds disclosed herein, including for the treatment of cancer.

In one aspect, the present disclosure provides caffeic acid derivatives of the formula:

##STR00001##

wherein the variables are as defined herein. In another aspect, the present disclosure provides pharmaceutical compositions and methods of using of the compounds disclosed herein, including for the treatment of cancer.

Described herein are crystalline forms of N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-ethoxyphenyl)-3-[(2R)-2-ethyl-4-[1-(trifluoromethyl)-cyclobutanecarbonyl]piperazin-1-yl]pyridine-2-carboxamide and methods of making the same. Such forms of N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-ethoxyphenyl)-3-[(2R)-2-ethyl-4-[1-(trifluoromethyl)-cyclobutanecarbonyl]piperazin-1-yl]pyridine-2-carboxamide are useful in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a melanocortin subtype-2 receptor (MC2R) antagonist compound.

Described herein are crystalline forms of N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-ethoxyphenyl)-3-[(2R)-2-ethyl-4-[1-(trifluoromethyl)-cyclobutanecarbonyl]piperazin-1-yl]pyridine-2-carboxamide and methods of making the same. Such forms of N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-ethoxyphenyl)-3-[(2R)-2-ethyl-4-[1-(trifluoromethyl)-cyclobutanecarbonyl]piperazin-1-yl]pyridine-2-carboxamide are useful in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a melanocortin subtype-2 receptor (MC2R) antagonist compound.

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.